What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

For US Audiences Only Approved Use Patient Information Full Prescribing Information Important Safety Information Select Cancer Type For Health Care Professionals

You are about to leave the lumakras.com/nsclc website and enter a website operated by a third party. Amgen is not responsible for and does not endorse or control the content contained on this third-party website.

Continue
Desiree H., a current LUMAKRAS® patient

How do I take LUMAKRAS®?

I take LUMAKRAS® at the same time each day.
It’s become part of my routine.”

Take LUMAKRAS® exactly as your health care provider tells you to take it. Do not change your dose or stop taking LUMAKRAS® unless your health care provider tells you to.

Patient story represents individual’s experience with LUMAKRAS®. Results may vary.

– Desiree H.
current LUMAKRAS® patient

How to take LUMAKRAS®

Take your prescribed dose of LUMAKRAS®:

how-to-take-lumakra-icon-1
Once daily by mouth1
how-to-take-lumakra-icon-2
At the same time every day1
how-to-take-lumakra-icon-3
With or
without food1

Your doctor will decide how much LUMAKRAS® you need. A typical dose is 960 mg1

  • Take LUMAKRAS® exactly as your doctor tells you to take it. Do not change your dose or stop taking LUMAKRAS® unless your doctor tells you to1
  • Take the number of tablets (pills) your doctor prescribes. If you have a side effect, talk to your doctor1
LUMAKRAS® is the only once-daily oral therapy for
 KRAS G12C–positive non-small cell Iung cancer (NSCLC)
taking-lumakras-therapy-icon-1

LUMAKRAS® recommended once-daily, starting dosage: 960 mg orally2

four 240 mg tablets taken once daily

LUMAKRAS® 240 mg tablets have a yellow color. They come in one bottle containing 120 tablets.

LUMAKRAS® (sotorasib) 240 mg tablets packaging and bottle by Amgen®

Please make sure you take the right number of tablets.2 LUMAKRAS® tablets are comparable in size to a dime.3 Speak with your doctor if you have any questions or if you experience a side effect.

If you have a side effect, your doctor may change your dose, temporarily stop, or permanently stop you from taking LUMAKRAS®1

When taking your daily dose of LUMAKRAS®

  • Swallow LUMAKRAS® tablets whole. Do not chew, crush, or split tablets1
If you cannot swallow LUMAKRAS® tablets whole:1
1.

Place your prescribed dose of LUMAKRAS® in a glass of 4 ounces (120 mL) of non-carbonated, room temperature water. Do not crush the tablets. Do not use liquids other than water

2.

Stir or swirl the cup for about 3 minutes until the tablets have broken down into small pieces. They will not completely dissolve. Drink immediately or within 2 hours. The appearance of the mixture may range from pale yellow to bright yellow

3.

Swallow the broken-down tablet mixture. Do not chew pieces of the tablet

4.

Rinse the glass with an additional 4 ounces (120 mL) of water and drink

5.

If the mixture is not consumed immediately, stir or swirl the mixture again to ensure the tablets are mixed into the water and drink

Important things to remember when taking LUMAKRAS®

If you take an antacid medicine, such as Tums®, take LUMAKRAS® either 4 hours before or 10 hours after the antacid. Speak to your doctor if you are on a proton pump inhibitor like Prilosec®, or an H2 blocker like Pepcid AC®1

If you miss a dose of LUMAKRAS®, take the dose as soon as you remember. If it has been more than 6 hours, do not take the dose. Take your next dose at your regularly scheduled time the next day. Do not take 2 doses at the same time to make up for a missed dose1

If you vomit after taking a dose of LUMAKRAS®, do not take an extra dose. Take your next dose at your regularly scheduled time the next day1

taking-lumakra-subbanner-bg

“You need to see what’s out there. You know, ask about your biomarker. Just don’t give up.”

– Desiree H.
current LUMAKRAS® patient

Patient story represents individual’s experience with LUMAKRAS®. Results may vary.

How to talk to your doctor

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.
    • are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the final dose.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
  • Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H2 blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

LUMAKRAS® may cause serious side effects, including:

  • Liver Problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).
  • Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever.
  • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

The most common side effects

  • The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
  • These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects.

What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer. Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

Please see LUMAKRAS® full Prescribing Information.

References: 1. NCI Dictionary of Cancer Terms. www.cancer.gov. Accessed January 27, 2025. 2. LUMAKRAS® (sotorasib) prescribing information, Amgen. 3. Ryan MB, et al. Nat Rev Clin Oncol. 2018;15:709-720. 4. Hong DS, et al. N Engl J Med. 2020;383:1207-1217. 5. Data on file, Amgen; [Analysis of AACR Genie v12].

References: 1. Hong DS, et al. N Engl J Med. 2020;383:1207-1217. 2. NCI Dictionary of Cancer Terms. www.cancer.gov. Accessed January 27, 2025. 3. LUMAKRAS® (sotorasib) prescribing information, Amgen. 4. Sotorasib CSR. Amgen; 2021. 5. Data on file, Amgen; [KRAS G12C Trials Sites]. 6. LUMAKRAS® (sotorasib) patient information, Amgen.

References: 1. LUMAKRAS® (sotorasib) patient information, Amgen. 2. LUMAKRAS® (sotorasib) prescribing information, Amgen. 3. Data on file, Amgen; [Sotorasib Tablet Size].

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.